Lapatinib and retinoic acid combination treatment of SKBR3 breast cancer cells

·Released Oct. 6, 2011 ·Updated May 2, 2014

Samples

Assays

Array Platforms

References

Description

SKBR3 cells, which bear both an HER2 and a RARA gene amplification, were treated for 12 or 48 hours with 100 nM retinoic acid, 100 nM lapatinib or the combination.The two drugs synergize and induce massive apoptosis. The aim is to find the molecular mechanism(s) of this synergism. Gene expression profiling was performed using Agilent two-color 4X44K arrays. Original processed data are available in the archive:

References

All-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ).

Zanetti A, Affatato R, Centritto F, Fratelli M, Kurosaki M, Barzago MM, Bolis M, Terao M, Garattini E, Paroni G.

PMID: 26018078

Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with co-amplification of ERBB2 and RARA

Gabriela Paroni, Maddalena Fratelli, Giorgio Gardini, Marcella Flora, Adriana Zanetti, Valeria Guarnaccia, Paolo Ubezio, Floriana Centritto, Mineko Terao and Enrico Garattini

Array Platforms

A-AGIL-28

Agilent Whole Human Genome Microarray 4x44K 014850 G4112F (85 cols x 532 rows)（32 items）

Sample Attributes

BioSourceType

fresh_sample

CellLine

SK-BR-3

DiseaseState

Breast adenocarcinoma

Organism

Homo sapiens

OrganismPart

mammary gland

provider

ATCC

Sex

female

Experiment Info

Accession

E-MEXP-3192

Type

transcription profiling by array

Organism

Homo sapiens

Released

Oct. 6, 2011

Updated

May 2, 2014

Submitter

Maddalena Fratelli

External Links

ArrayExpress source

Analysis Services

Lapatinib and retinoic acid combination treatment of SKBR3 breast cancer cells

Contact

WeChat Official Account